A benign cause of hyperandrogenism in a postmenopausal woman by Roque, João José Nunes et al.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
© 2021 The authors https://edm.bioscientifica.com/
 PublishedbyBioscientificaLtd
ID: 20-0054; February 2021
DOI: 10.1530/EDM-20-0054
Hyperandrogenism in  
post-menopause
J J N Roque and others
A benign cause of hyperandrogenism in a 
postmenopausal woman
João José Nunes Roque1, Irina Borisovna Samokhvalova Alves2, 
Ana Maria de Almeida Paiva Fernandes Rodrigues3 and Maria João Bugalho1,4
1Department of Endocrinology, Hospital de Santa Maria, Lisboa, Portugal, 2Department of Pathology,  
Hospital de Santa Maria, Lisboa, Portugal, 3Department of Obstetrics & Gynecology, Hospital de Santa Maria, Lisboa, 
Portugal, and 4Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal 
Summary
Menopause is a relative hyperandrogenic state but the development of hirsutism or virilizing features should not be 
regarded as normal. We report the case of a 62-year-old woman with a 9-month history of progressive frontotemporal 
hair loss and hirsutism, particularly on her back, arms and forearms. Blood tests showed increased total testosterone of 
5.20 nmol/L that remained elevated after an overnight dexamethasone suppression test. Free Androgen Index was 13.1 
and DHEAS was repeatedly normal. Imaging examinations to study adrenals and ovaries were negative. The biochemical 
profileandtheabsenceofimaginginfavorofanadrenaltumormadeusconsidertheovarianoriginasthemostlikely
hypothesis. After informed consent, bilateral salpingectomy-oophorectomy and total hysterectomy were performed. Gross 
pathology revealed ovaries of increased volume and histology showed bilateral ovarian stromal hyperplasia. Testosterone 
levels normalized after surgery and hirsutism had completely subsided 8 months later.
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 • Menopause is a relative hyperandrogenic state
 • Hirsutism and/or virilizing features, in a postmenopausal woman, should raise the hypothesis of a malignant cause
 • Intheabsenceofanidentifiableovarianoradrenaltumor,theovarianoriginremainsthemostlikely




In healthy women, ovarian androgen production declines 
progressively with age, while estrogen synthesis declines 
abruptly after menopause. A rise in gonadotropin 
levels and a decrease in SHBG concentration are also 
noted in postmenopausal women. Thus, mild signs of 
hyperandrogenism may be part of the aging process (1). 
However, the development of hirsutism accompanied 
by virilizing features like maletype alopecia, acne, voice 
deepening and clitoromegaly must prompt adequate 
investigation, since those could be manifestations 
of a malignant androgen-secreting tumor, the 
commonest cause of recent onset clinically exuberant 
hyperandrogenism in postmenopausal women (2). 
The present case documents a benign but rare cause 
of hyperandrogenism in a postmenopausal woman whose 
final diagnosis was established by histology. 
Case presentation
A 62-year-old woman presented in the Endocrine Clinic 
with a 9-month history of new-onset and progressive 
hair loss, scalp hair thinning, hirsutism and no other 
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virilizing signs or symptoms (Fig. 1). Her menarche 
was at 13 years, she had regular menses until reaching 
menopause at 51 years and there was no pre or post-
menopausal metrorrhagia history. She reported one 
uneventful pregnancy with term vaginal delivery, one 
7-month in utero death for no clearly understood reason 
and one voluntary termination of pregnancy. She was 
diagnosed with essential hypertension and dyslipidemia 
at the age of 50 years and had progressive weight gain 
over the years. At the age of 56 years, she was diagnosed 
with type 2 diabetes. No previous surgeries were reported 
and family history was unremarkable. Her regular 
medication was metformin (2000 mg/day), losartan (50 
mg/day) and spironolactone (25 mg/day). She was not 
taking any drug with androgenic effects. On physical 
examination, she had obesity (abdominal perimeter 109 
cm, BMI 37 kg/m2, class II of WHO classification) and had 
evident frontotemporal alopecia and increased terminal 
hair growth, particularly on her back, arms and forearms. 
There were no other virilizing signs like acne or voice 
deepening. Skin hyperpigmentation, reddish striae and 
acanthosis nigricans were absent. Blood pressure and heart 
rate were normal.
Investigation
Initial diagnostic tests, under the usual medication, 
documented increased total testosterone (5.20 nmol/L); 
androstenedione of 8.73 nmol/L; gonadotropins in the 
menopause range - LH: 23.9 mIU/mL; FSH: 22.8 mIU/
mL; SHBG: 32.3 nmol/L; and Free Androgen Index: 13.1. 
The other hormonal parameters particularly DHEAS, 
17-hydroxyprogesterone, IGF1, prolactin and ACTH were 
normal. Lipid profile exhibited mixed dyslipidemia (total 
cholesterol of 6.54 mmol/L, triglycerides of 2.47 mmol/L, 
HDL: 1.32 mmol/L, LDL: 4.09 mmol/L). 
After an overnight dexamethasone suppression 
test, cortisol was suppressed (30.34 nmol/L), but total 
testosterone persisted elevated (4.23 nmol/L).
The patient underwent abdominal and pelvic CT 
scan which failed to reveal any adrenal or ovarian 
lesion. Transvaginal ultrasound report mentioned 2 
small leiomyomas without reference to other alterations, 
particularly of the ovaries.
The high levels of testosterone favored a malignant 
etiology. Furthermore, normal values of DHEAS and 
the absence of imaging evidence of an adrenal tumor 
suggested the ovarian origin of hyperandrogenism as the 
most likely hypothesis.
Treatment 
Bilateral salpingectomy-oophorectomy and total 
hysterectomy, via laparotomy, were performed, after 
discussion by a multidisciplinary team and taking into 
account the patient's perspective and preferences. Gross 
pathology revealed slightly enlarged ovaries (right ovary: 
3.5 × 2 × 1.7 cm; left ovary: 3 × 2 × 1.7 cm) and normal 
endometrium. Histology identified bilateral ovarian 
stromal hyperplasia (Figs 2 and 3).
Outcome and follow-up 
Surgical intervention proved to be remarkably effective, 
as the patient is still on remission. Total testosterone 
levels became normal 1 month after surgery and clinical 
improvement was first noted 8 months later (Fig. 4).
Figure 1
Marked skin redness and hirsutism on the back and right upper limb. 
Captionedonfirstconsultation.
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This clinical case illustrates some of the diagnostic 
challenges of postmenopausal hyperandrogenism. 
A careful clinical history and physical examination 
are crucial for a correct diagnosis, just as the adequate 
prescription and interpretation of complementary exams. 
Our patient had a relatively fast and exuberant clinical 
course, which initially pointed toward a malignant 
etiology and prompted rapid investigation. Persistence of 
elevated serum testosterone levels after dexamethasone-
suppression test reinforced the clinical hypothesis. 
Noteworthy, the patient was under Spironolactone 
treatment that is an inhibitor of aldosterone and also a 
weak competitive inhibitor of androgen binding to the 
androgen receptor and a weak inhibitor of testosterone 
synthesis. The biochemical profile, as well as a CT scan 
negative for adrenal tumors, did not favor the adrenal 
etiology. On the contrary, ovarian tumors are easily missed 
by imaging making an ovarian androgen origin more likely. 
Accordingly, we decided to perform a bilateral salpingo-
oophorectomy with hysterectomy, which afterward 
proved to be curative (Fig. 4). Histological diagnosis was 
bilateral ovarian stromal hyperplasia (Figs 2 and 3). This 
is a benign entity usually referred in close association 
with the presence of nests of luteinized theca cells in 
the ovarian stroma (termed as Ovarian Hyperthecosis), 
which curiously were not identified on our histological 
examination (Figs 2 and 3). Its etiology is still not well 
understood. It is most frequently seen in postmenopausal 
women and is characterized by severe clinical and 
biochemical hyperandrogenism and insulin resistance, 
generally more exuberant than observed in other benign 
etiologies (3). Definitive diagnosis is established by 
histology. Due to increased androgen secretion, these 
Figure 2




Ovarian Stromal Hyperplasia. Dense proliferation of uniform, oval to 
spindle-shaped stromal cells. No cellular atypia, mitosis or luteinized 
thecacells(hematoxylin–eosinstaining,originalmagnification×200).
Figure 4
Complete resolution of presenting signs 8 months after surgery.
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patients can also have increased plasma androstenedione 
and, as a consequence of peripheral aromatization, 
high levels of estrogens. Thus, the risk of endometrial 
hyperplasia and endometrial carcinoma is increased (3, 
4). Biochemical testing typically shows high serum total 
testosterone (over 5.20nmol/L), normal or suppressed LH 
and FSH, hyperglycemia, variable serum androstenedione, 
normal DHEAS, 17-hydroxyprogesterone, prolactin and 
IGF1. Ultrasonography usually shows bilateral ovarian 
volume increase, which was not reported in our case, 
although observed by the pathologist (5). Magnetic 
resonance can identify homogenous T2-hypointensity 
and mild enhancement of the ovaries (6). Ovarian and/
or adrenal venous sampling can also be used when 
imaging tests are negative. However, this should only 
be performed in premenopausal women contemplating 
pregnancy, since it requires a very experienced radiologist 
and there is still no consensus of whether it can localize 
the androgen source. Treatment of suspected ovarian 
stromal hyperplasia/ovarian hyperthecosis is bilateral 
oophorectomy when fertility is not a concern. Long-term 
gonadotropin-releasing hormone agonist treatment is 
an alternative in younger women aiming to preserve 
fertility (7).
Until now, less than 30 cases of postmenopausal 
hyperandrogenism caused by ovarian stromal hyperplasia 
were reported; in all, hyperplasia coexisted with ovarian 
hyperthecosis (luteinized theca cells) which reinforces the 
singularity of the present case.
Patient’s perspective
The problem was bothersome and with a negative impact on her self-
image. It started suddenly and unexpectedly. Furthermore, she had never 
met a woman who had had a similar situation. After surgery, physical 
featuresimprovedfast.At8-monthfollow-upvisit,shewasverysatisfied
and grateful to her medical team.
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